BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Acetaminophen
,
rs2476601
,
SNCA
,
Response to oxidative stress
,
Ischemia
,
Prostate
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
braf inhibitor
Summary
General Info
Curated Studies
Most Correlated Studies
Normal dermal fibroblast and malignant melanoma cells treated with BRAF inhibitor vemurafenib
Melanoma BRAF and NRAS mutant cells resistant to BRAF inhibitor PLX-4720 or MEK inhibitor trametinib
Melanoma cell lines with BRAF-V600E mutation & selected for resistance to BRAF inhibitor SB590885
Malignant melanoma A375 cells treated with BRAF inhibitor vemurafenib
Lung adenocarcinoma cells with YAP1 shRNA and treated with MEK or BRAF inhibitor
Explore Curated Studies Results
Literature
Most Relevant Literature
Design, synthesis and characterisation of a novel type II B-RAF paradox breaker inhibitor.
Recent advances in B-RAF inhibitors as anticancer agents.
On the development of B-Raf inhibitors acting through innovative mechanisms.
Cures with B-Raf inhibitors as single agents in metastatic B-Raf mutated melanoma: Curb your enthusi…
Structure-Based and Knowledge-Informed Design of B-Raf Inhibitors Devoid of Deleterious PXR Binding.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Me…
Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Tre…
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trame…
Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BR…
Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ